GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

GSK respond to negative NICE recommendation on Tykerb

GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. The company says “we strongly believe that the wrong decision has been made for patients, doctors and the NHS”

GSK publish series of Rho kinase I (ROCK1) inhibitors

GSK have published a series of dihydropyrimidine Rho kinase I (ROCK1) inhibitors

GSK publish series of PLK-1 inhibitors

GSK have published a seies of Imidazo[5,1-f][1,2,4]triazin-2-amine polo-like kinase 1inhibitors

GSK publish seres of CDK inhibitors

GSK have published a series of pyrazolo[1,5-b]pyridazine CDK inhibitors

GSK publish series of p38 MAP kinase inhibitors

GSK publish series of Pyrazolo[1,5-a]pyridine p38 MAP kinase inhibitors

Pazopanib demonstrates efficacy in Sarcoma and Ovarian cancer

Phase III data presented at the European of Medical Oncology (ESMO) show pazopanib to be effective in soft tissue sarcoma (STS), epithelial ovarian cancer, and non small cell lung cancer. GSK plan to initiate Phase III trials in other cancer types.

GSKs Tykerb (lapatinib) effective in advanced head and neck cancer

Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lapatinib) is effective in advanced head and neck cancer

GSK and Cellzome sign strategic alliance to discover kinase-targeted therapeutics

Cellzome and GlaxoSmithKline have entered in to an alliance to discover, develop and market novel kinase  therapeutics to treat inflammatory diseases.

Combination of a sheddase inhibitor INCB3619 with lapatinib improves anti-tumor effect

Researchers have shown that the addition of sheddase inhibitor INCB3619 to lapatinib treated cells increases antitumor activity